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ABSTRACT
The goal of part I of this thesis was to isolate pure anti cancer compounds from the Russian
plant Sanguisorba officinalis. This plant was selected for investigation because it showed 100%
activity against leukemia (L1210 mouse leukemia cells) during the preliminary screening of
approximately 100 Russian plant extracts. This work has resulted in the isolation of novel
compound 11 using traditional chromatography techniques. Compound 11 was characterized
with spectroscopic techniques such as IR, 1H NMR,

13

C NMR, DEPT, DQCOSY and MS.

Compound 11 was assigned the structure dipentyl 2-(4-(pentan-3-yl) phenyl) malonate.
The goal of part II of this thesis was to synthesize novel ethers of podocarpic acid. Ethers
are of great interest in biological studies and pharmaceutical applications because of their wide
variety of uses in the treatment of various diseases. A novel family of ether derivatives was
synthesized using podocarpic acid (a natural tricyclic diterpene derived from podocarpus
species) as a template. Novel ether derivatives of podocarpic acid were synthesized from
podocarpic acid in three steps. The first step involved methylation of podocarpic acid with
dimethyl sulfate to form methyl-o-methyl podocarpate. The second step was iodination of
methyl-o-methyl podocarpate with iodine in presence of a mercury catalyst to form 13-iodo
methyl-o-methyl podocarpate. This was followed by formation of novel aliphatic ethers using a
copper catalyst. Thus this research had led to the discovery of new methodology for synthesis of
three novel aliphatic ether derivatives of podocarpic acid. These ethers will be tested for their
biological activity against various types of cancer, tuberculosis by National Institutes of Health.
.
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PART I: ISOLATION OF DIPENTYL 2-(4-(PENTAN-3-YL) PHENYL)
MALONATE FROM SANGUISORBA OFFICINALIS LABILL

1. Introduction

1.1. Natural Products and Drug Discovery:
Modern medicine has had great success in discovering the new drugs from natural
sources (animals, plants and microorganisms) as well as synthetic methods for the
treatment of various infectious diseases like malaria, HIV, tuberculosis and cancer.
Throughout the history of mankind there has been a rich tradition in the use of herbal
medicine for the treatment of human ailments1 with the first records dating from about
2600 BC in Mesopotamia2. This could possibly be because drugs obtained from plants
may have fewer side effects and may reduce the possibility of microorganisms
developing resistance against drugs. Today, plant-based medicines are being used by
approximately eighty percent of the world’s population for primary healthcare. Over
50% of the FDA approved anticancer drugs since 1960 have come from natural
resources, mainly terrestrial plants3. Approximately one-third of the top-selling drugs in
the world are natural products or their derivatives4. Approximately twenty five percent
of the prescription drugs in the United States are the active constituents of higher
plants5. Some plant based medicines are quinine (the anti malarial drug from Cinchona
bark species) digitoxin (used for treatment of congestive heart failure and isolated from
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Digitalis purpurea) taxol (the anti- tumor drug from Taxus brevifolia) and
ephedrine,(the anti asthma drug from Ephedra sinica).

1.2. Etiology of Cancer and treatment:
Cancer is the second leading cause of death in the United States. Approximately thirty
percent of the people develop cancer during their life time6. Cancer results from the
uncontrollable abnormal growth of cells. Because of no differentiation between cancer
and normal cells, cancer cells upon metastasis spreads to other tissues and organs.
Hence cancer is a life threatening pandemic disease and must be treated. There are
many anti cancer drugs, with a majority7 of them derived from plant and animal
sources. Anticancer drugs act by interfering with cancer cell growth and reproduction.
There are many advanced methods for the treatment of cancer; the method to use
depends on the decision made by a panel of doctors based on the type of cancer and its
intricacies.
The most common types of cancer include colorectal cancer, breast cancer, prostate
cancer, lung cancer, skin cancer and leukemia. Leukemia, the most common type of
blood cancer affects about 30% of children in the United States. Crowley8, the author of
the book Introduction to human diseases, has explained the nature of the disorder
leukemia. The term leukemia refers to a neoplasm of hematopoietic tissue. Leukemia is
a malignant disease of bone marrow and blood, characterized by uncontrolled
accumulation of white blood cells. There are two types of white blood cells called
myeloids, which kill bacteria and lymphocytes, which have a significant role in the
management of immune system. In contrast to solid tumors, which form nodular
2

deposits, leukemic cells diffusely infiltrate the bone marrow and lymphoid tissues, spill
over into the blood stream, and infiltrate through out the various organs of the body.
There are more than dozen types leukemia, out of these, four9 types of leukemia occur
most frequently, including acute lymphocytic leukemia (ALL), chronic lymphocytic
leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous
leukemia (CML). Leukemia is the most common cancer that affects children under the
age of 19. About 78% of childhood leukemias10 are of ALL type. ALL results when
DNA of a cell in bone marrow has genetic injury. This involves accumulation of cells
called lymphoblasts or leukemic blasts, which fail to function as normal red blood cells
results in anemia, thrombocytopenia, and neutropenia in the blood. Myeloblastic
leukemia or myelogenous leukemia (AML) develops when there is a defect in the cells
in the bone marrow. AML occurs more often in adults. CML is known as
myeloproliferative disorder, the disease in which bone marrow cells proliferate outside
the bone marrow tissue. CLL results from gradual accumulation of lymphocytes. The
leukemic cells may be mostly mature and can perform certain functions as in chronic
lymphocytic or myelogenous leukemia or may be extremely primitive as in acute
lymphocytic or myelogenous leukemia and can not perform any functions and must be
treated immediately. The overproduction of white cells in leukemia may be reflected in
the blood by a very high white blood cell count. In some cases of leukemia white cells
multiplication mostly confined to bone marrow as in acute or chronic myelogenous
leukemia.
Though treating leukemia is difficult, there is a hope to get success. Management of
disease currently relies on a combination of early diagnosis either by bone marrow
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biopsy or lumbar puncture and aggressive treatment, which may include one or more
treatments such as surgery, radiation therapy, chemotherapy, immunotherapy and bone
marrow transplantation available to treat leukemia. Researchers are focusing their
studies on developing new effective methods or drugs to treat leukemia. Surgery
involves removal of the whole tumor to avoid spreading of cancer to other parts of the
body. Radiation therapy is done by passing high energy particles or waves, such as γ
rays, x rays, electrons or protons to destroy or damage cancer cells. This works by
breaking the strand of DNA inside the cancer cell, which prevents the growth and
division of cancer cells. Immunotherapy (biological therapy) has proven useful in
treating cancer within last few decades. This is the treatment done by using certain parts
of immune system of the patient’s body by stimulating the immune system or by using
the man made immune system proteins. Nowadays three types of immune therapy are
available immune cell administration, use of vaccines and antibody treatment.
Immunotherapy11 is the most promising treatment for leukemia and certain other
cancers like kidney cancer, breast cancer, prostate cancer, colorectal cancer and lung
cancer. Bone marrow transplantation is required for certain leukemia patients if their
bone marrow has destroyed by disease, chemotherapy or radiation therapy. This is the
best method available for some patients with acute leukemia and chronic granulocytic
leukemia who have not responded to other conventional treatments12. The patient’s own
bone marrow is destroyed by large doses of anti cancer drugs and radiation. Then
several hundred milliliters of bone marrow are aspirated from multiple sites in the
pelvic bones of suitable donor, filtered to break up the clusters of marrow cells and
form a homogeneous suspension of individual cells, and then inject to the patient. The
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marrow cells circulate in the patient’s blood but they become stable and grow in the
marrow, produce new population of leukemia free marrow cells. As the bone marrow of
donor is a foreign tissue, to avoid rejection, patient’s immune system should be
suppressed during transplantation. The last and most viable method for treating
leukemia is Chemotherapy. Chemotherapy means taking medicines or drugs orally or
intravenously to treat cancer. Cancer chemotherapy has been there to treat cancer since
195013. Chemotherapy is helping cancer patients to have a prolonged happy life. Every
method in use for the treatment of cancer involves chemotherapy at some stage during
the treatment period.
A natural product that has been discovered recently by Shinya Kimura13 et al for
treatment of leukemia is GUT 70 (1), isolated from the stem bark of Callophylum
brasiliense, which was collected from Brazil. GUT 70 (1) is a tricyclic coumarin
named 5-methoxy, 2, 2-dimethyl-6- (2-methyl-1-oxo-2-butenyl) -10-propyl-2H, 8Hbenzo (1,2-b; 3, 4-b) dipyran-8-one, which has shown antileukemic activity against
five human leukemic cell lines (BV 173, K562, KALM 6, Hl-60 and SEM).

o

(1) GUT-70
o

o

o
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Amooranin (2) is a novel plant triterpenoid that was isolated from Amoora rohituka by
Chappail Ramachandran14 et al. Compound 2 exhibited potent anti leukemic
activity as was demonstrated by inducing G2 + M phase arrest during cell cycle in
leukemia and colorectal carcinoma.

(2) Amooranin

Zhang J T 15 reported that Indirubin (3) was isolated from the leaves of Indigo naturalis
which is a native Chinese plant. Compound 3 exhibited anti leukemic activity without
bone marrow inhibition.

O

(3) Indirubin

NH

N
H
O
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Aryanti16, Bintag and Maria reported that Artemisinin (4), (a sesquiterpene lactone),
obtained from the transformed root of cultured Artemisia cina that was produced by
infection of stems and leaves with agro bacterium rhizogenes. Compound 4 had a high
inhibition activity on leukemic K562 cells with the IC50=1ppm

H
O

(4) Artemisinin
O
H

O

O

H
O

Two indole quinoline derivatives cryptolepine (5) and neocryptolepine (6) were
isolated from the roots of theAfrican plant Cryptolepis sanguinolenta. Their
cytotoxicity was tested on murine and human leukemia cells. Christian bailey et al17
reported that cryptolepine (5), and to the lesser extent neocryptolepine (6), showed
antileukemic activity by massive accumulation of p388 cells in G2+M phase of cell
cycle.
H3C
N+

(5) Cryptolepine

N
H

7

(6) Neocryptolepine

N+
CH3

N
H

Goniothalamin (7)18,19was isolated from Bryonopsis laciniosa by Ali Abdul et al. The
cytotoxicity of compound 7 was investigated on a T-lymphoblastic leukemia cell line.
The results were compared to Etoposide anticancer activity, which indicated that
Goniothalamin (7) had a potent apoptic activity. This was confirmed by observing the
inter nucleosomal DNA fragmentation.

O

O

(7) Goniothalamin

H

The novel norilludalane sesquiterpene puraquinonic acid (8) was isolated by Becker
and coworkers20 from mycelial cultures of Basediomycete mycenae Pura. Puraquinonic
acid (8) induces differentiation of 30-40% of HL-60 cells into granulocyte or
monocyte/macrophage like cells at 380µm. U-937 cells were affected to a lesser extent
at the same concentration.
8

O
COOH

(8) Puraquinonic acid
HO

O

Erkel and coworkers21 isolated nidulal (9) novel inducer of differentiation of human
HL-60 promyelocytic leukemia cells) from the fermentation of basidiomycete Nidula
candida, together with small quantities of niduloic acid (10). Both are bisabolane
sesquiterpenes.They reported that nidulal(9) activated transcription factor complex AP1 mediated expression of secreted alkaline phosphatase in COS-7 cells.

O

O O
CHO

H3C

(9) Nidulal

O

HOOC

O
COOH

(10) Niduloic acid

H3C

Thus a variety of novel natural products have been isolated that may yield new drugs for
the treatment of leukemia.
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1.3. The Goal of This Research:
The goal of this work was to isolate pure compounds, which can inhibit the growth of
cancer cells, from methylene chloride extract of Sanguisorba officinalis labill. This
plant was selected for investigations as the preliminary screening of methylene chloride
extract of this plant from Russia had shown hundred percent activity against leukemia
and sixty seven percent anti thrombin activity22.

1.4. Sanguisorba Officinalis and its origin:
Although this plant material has collected from Russia, Sanguisorba is native to China
belongs to family Rosaceae, a large family of 95 genera and 2800 species23
Sanguisorba officinalis labill contains about 25 species. They grow in moist meadows
and shady places, almost all over Europe. It grows in a wild from Maine to Minnesota
in USA. The aborigines (native Chinese) have traditionally used sanguisorba to heal
wounds and to treat fungal infections. Mainly they used in cure of heavy periods and
hemorrhage. The extracts of Sanguisorba have been used as food additives, to make tea
and in cosmetic formulations. Recently this plant has got much attention to investigate
its medicinal uses. Research data has demonstrated that the extracts exhibit various
biological activities such as antidiarrheal, antibacterial and antiemetic. It is a valuable
astringent and is used for gastrointestinal problems, diarrhea, dysentery, ulcerative
colitis and abdominal uterine bleeding. The crude extracts from Sanguisorba officinalis
showed significant antimicrobial activity24 against both Gram-positive and Gramnegative bacteria, when tested against five species of microorganisms (Staphylococcus
aureus, Pseudomonas aeruginosa, Escheria coli, Bacillus subtilis, Candida albicans ).
10

1.5. Previously isolated compounds from Sanguisorba Officinalis:
Previously several compounds have been isolated from Sanguisorba Officinalis,
including ursolic acid25, sanguisorbigenin, 2,4-dihydroxy-6-methoxy acetophenone,
3,3’,4-tri (O-methyl) ellagic acid, oleanolic acid, masilinic acid26, sanguisorbin,
terpenyl acetate27 and grandinin. The structures of these compounds shown in table 1.
Ursolic acid is a triterpenoid that present in especially waxy coatings of leaves and in
fruits, such as apples and pears. It can serve as insect repellant and anti microbial
agent28. Although triterpenoids have limited medicinal use, recent studies indicate them
as potential drug leads29. Ursolic acid has shown significant cytotoxicity in the
lymphocytic leukemia cells P388 with ED50 3.15mg/mL, L1210 with ED50 4.00
mg/mL30. The anti tubercular activity of ursolic acid has also been reported31.
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Table 1 Structures of previously isolated compounds from Sanguisorba officinalis

General structure

Compound name

Ursolic acid

Maslinic acid

11,12-Dehydro ursolic acid
lactone

12

AcO

Me
C

Terpinyl acetate

Me
Me

Me
Me

Me

α-pinene

HO

COOH

Gallic acid
HO
OH

OH
OH
HO

O

Catechin

OH
OH
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2. Results and Discussion

Sanguisorba officinalis was selected for this investigation because preliminary
screening of the methylene chloride extract from this plant had shown hundred percent
activity against leukemia when it was tested on mouse leukemia cells. Dried leaves of
the plant material were collected from Russia and extracted with methylene chloride
followed by methanol in a soxhlet apparatus for 12 hours. The solvent was removed in
vacuum to obtain methylene chloride and methanol extracts. The methylene chloride
extract was chromatographed on silica gel and then eluted with mixed solvents such as
hexane, methylene chloride; chloroform and methanol in the order of increasing
polarity.107 fractions were obtained. The eluent fractions were collected and monitored
by TLC on silica gel with different solvent systems ranging from 25%:75% hexane:
methylene chloride to 50%:50% hexane: methylene chloride and the results were
observed under UV light. Based on these results fractions 1-27 were mixed and further
chromatographed in a small liquid chromatography column to obtain twenty fractions.
From the resultant fractions, a pure compound was isolated. This compound was a
highly viscous liquid with pale yellow color and was proved to be dipentyl 2-(4(pentan-3-yl) phenyl) malonate based on the spectroscopic data obtained. Normal phase
open column chromatography results are shown in table 2 and table 3.

14

Table 2 Column Chromatography (I) of Sanguisorba Officinalis Labill
Fractions

Eluent

Weight (grams)

F 1-7

100% hexane

0.32

F 8-11

20% CH2Cl2 in hexane

1.69

F 12-20

30% CH2Cl2 in hexane

3.06

F 21-25

40% CH2Cl2 in hexane

1.34

F 26-30

50% CH2Cl2 in hexane

0.56

F 31-40

60% CH2Cl2 in hexane

2.78

F 41-50

70% CH2Cl2 in hexane

0.68

F 51-59

80% CH2Cl2 in hexane

3.57

F 60-74

90% CH2Cl2 in hexane

3.20

F 75-79

100% CH2Cl2

1.84

F 80-84

50% CH2Cl2 in CHCl3

2.34

F 85-89

75% CH2Cl2 in CHCl3

2.17

F 90-93

100% CHCl3

1.98

F 94-99

50% CHCl3 in CH3OH

2.20

F 100-107

100% CH3OH

3.12
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Table 3 Column Chromatography (II) of Sanguisorba Officinalis Labill
Fractions

Eluent

Weight (grams)

F 1-2

100% hexane

0.34

F 3-4

20% CH2Cl2 in hexane

0.38

F 5-6

50% CH2Cl2 in hexane

0.28

F 7-9

75% CH2Cl2 in hexane

0.52

F 10

100% CH2Cl2

0.48

F 11-13

50% CH2Cl2 in CHCl3

1.25

F 14-15

75% CH2Cl2 in CHCl3

1.54

F 16

100% CHCl3

0.87

F 17-18

50% CHCl3 in CH3OH

0.68

F 19

75% CHCl3 in CH3OH

0.43

F20

100% CH3OH

0.62
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Figure 1 GC of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

The purity of the isolated compound was evaluated with gas chromatography. The GC
showed a single peak with retention time tr = 5.68 min.
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Figure 2 HPLC of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

High performance liquid chromatography (HPLC) was used for separating and
determining species in different materials. Normal phase HPLC was performed by
using different compositions of several solvent systems that are normally used and the
best results were obtained with hexane and methylene chloride (20 % to 80%).The
chromatogram is shown in figure 4.
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Figure 3 UV spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

The UV spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11) showed the
absorption maxima at λmax: 200 nm, 268 nm, 298 nm, which suggested the presence of
a conjugated system.

19

Figure 4 IR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

The IR spectrum has showed absorption maxima at λmax 1740 cm-1 for an ester carbonyl
group, 1121 cm-1 and 1267 cm-1 for C-O stretch and 1465 cm-1 and 1600 cm-1 for an
aromatic system.
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Figure 5 1H NMR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

1

H NMR, 13C NMR, DEPT and DQCOSY data were obtained to complete the structure

proof of compound 11. The spectra were run in deuterated chloroform and deuterated
acetone. The 1H NMR showed signals between 0.8 and 1.1 ppm for four methyl groups,
between 1.2 and 1.6 ppm for eight methylene groups, between 2.2 and 2.8ppm for two
methine groups and between 4.1 and 4.3 ppm for two methylene groups attached to
oxygen. The signals at δ 7.5 and δ 7.7 correspond to aromatic protons. 1H NMR is
shown in Figure 5.
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Figure 6 13C NMR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11).

The DEPT 13C NMR spectrum (Figure 7) revealed four methyl carbons at δ 11.436 and
δ 14.52. The methylene carbons appeared at δ 23.428, δ 24, δ 29.348 and δ 30.775,
while the methine carbons appeared at δ 44.9, δ 128.9 and δ 130.9. The quaternary
carbons appeared at δ 132.5 and the ester group carbon appeared at δ 167.7. The
NMR spectrum is shown in Figure 6.

22
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C

Figure 7 13C DEPT spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11).
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Figure 8 DQCOSY spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11).

The DQCOSY showed that the methylene carbons attached to oxygen are attached to
methylene groups and benzene is disubstituted. Some of methylene groups attached to
methyl groups.
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Figure 9 Mass spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11).

The basic fragmentation pattern of proposed structure of dipentyl 2-(4-(pentan-3-yl)
phenyl) malonate is illustrated in figure 10.
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m/Z 113, C6H9O2
m/Z 277, C18H29O2
O

-CO

2,

-CH

3

O

m/Z 148, C11H16

m/z 71, C5H11

Figure 10 Scheme summarizing the mass fragmentation pattern of dipentyl 2-(4-pentan3-yl) - phenyl) malonate (11).
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The UV, IR, 1H NMR, 13C NMR and MS data confirms the structure of compound 11 as
dipentyl 2-(4-pentan-3-yl) phenyl) malonate.

O

O

O

(11) Dipentyl 2-(4-pentan-3-yl) phenyl) malonate.

O

Figure 11

The proposed structure for compound 11, isolated from Sanguisorba

officinalis
Structure elucidation of compound 11 was done as follows. The UV spectrum
showed the absorption maxima at λmax: 200 nm, 268 nm, 298 nm, which suggested the
presence of a conjugated system. The IR spectrum has showed absorption maxima at
λmax 1740 cm-1 for an ester carbonyl group, 1121 cm-1 and 1267 cm-1 for C-O stretch
and 1465 cm-1 and 1600 cm-1 for an aromatic system. Hence at this juncture, the
presence of benzene ring and ester groups were confirmed.
and

-C-O-R
O

To know which R group was attached to ester group and benzene ring, the 1H NMR
was performed. This showed the presence of Para disubstituted benzene ring by
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showing doublet of doublets in between δ 6.0 ppm and δ 8.0ppm also showed the
presence of 4 methyl groups, 8 methylene carbons, 2 methine carbons and 2 CH2-O
moieties. At this point part of the compound 11 structure was as shown below.
R

R'
R and R’ groups are different. For further information about R and R’ groups 13C NMR

and DEPT were performed.

13

C NMR showed 12 different signals indicated that

compound 11 should be symmetric. The DEPT spectrum showed the presence of 2
types CH3, 4 types CH2, 1 type CH2–O and 4types CH groups.
R

R

R'

R'

The DQCOSY showed that CH2-O moieties are attached to CH2 carbons. The HRMS
gave the molecular formula for compound 11 as C24H38O4 and the fragmentation
pattern was consistent with the mass spectrum obtained.
Hence from all the above information, by considering carbon-carbon connectivity’s in
DQCOSY spectrum and mass spectral fragmentation pattern the structure of compound
11 was confirmed as dipentyl 2-(4-pentan-3-yl) phenyl) malonate.
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3. Experimental

3.1 General experimental procedure
UV spectrum was obtained in hexane with a Carry 500 scan UV-NIR
spectrophotometer and the absorption maximum was given in nm. IR spectrum was
recorded on a Perkin Elmer Spectrum One FT-IR spectrometer. The NMR spectra were
obtained on a Varian 300 MHz and the solvents used were deuterated chloroform and
deuterated acetone. GC-MS spectra were recorded on Trace GC/Trace DQC from
Finnegan. A capillary column of RTX-5MS with a length of 15 m and 0.25 mm ID was
used. The oven temperature was initially set up to 90C for 7 minutes then programmed
to reach 250C. HPLC was run on Gilson equipment, using a silica gel column normal
phase and the solvent used was a mixture of hexane and methylene chloride.

3.2 Extraction, isolation and structure determination
The plant material, Sanguisorba officinalis, was collected from Russia. The dried
leaves (1.00 Kg) were extracted with methylene chloride followed by methanol for 12
hrs by using soxhlet apparatus. After extraction, the solvents were evaporated by using
rotary evaporator and the residue from both extracts was collected. 97 g and 124 g of
residues were obtained from methylene chloride and methanol extracts respectively.
Then open column chromatography was carried out on silica gel (E.Merk, 70-230
mesh). 107 fractions were collected by using different solvent systems in the order of
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increasing polarity. All fractions were analyzed by TLC. Fractions with same Rf value
were mixed and again open column chromatography was carried out to isolate a pure
compound. Pre-coated preparative silica gel GF-254 plates (20x20 cm, 0.5 mm thick,
E.Merk) were used for thin layer chromatography.
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PART II: SYNTHESIS OF A NOVEL FAMILY OF ETHERS OF
PODOCARPICACID

1. Introduction

1.1 The Goal of this research:
The goal of this research was to synthesize a novel family of ethers of podocarpic acid
by using podocarpic acid as a template. Previous research studies showed that
podocarpic acid derivatives were biologically active as well as many compounds with
ether functionality. Therefore the premise of this work was to synthesize a library of
ethers of podocarpic acid so that their biological activity will be evaluated by the
National Cancer Institute against 60 human cancer cell lines for their anti tumor activity
and by National Institute of Allergy and Infections Diseases for their activity against
tuberculosis.

1.2 Natural products and their anti tumor activity:
Natural products from plants, fungi and bacteria have been used as traditional medicine
for the treatment of various diseases and cancers. According to annual report on
medicinal chemistry from the year 1983 to 1994, 60% to 75% of the prescription drugs
are natural products or their derivatives32. There is a huge supply of unexploited natural
products with significant biological activity. Many of these compounds have antitumor
activity33. As an example etoposide (12), antineoplastic agent, a semi synthetic
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derivative of podophyllotoxin, extracted from root of Podophyllum peltatum, which
was shown in figure 12.

(12) Etoposide

Figure 12 Podophyllum peltatum
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Boik John, the author of the book Natural compounds in cancer therapy34, described
about seven strategies to cure cancer. Those are: reducing genetic stability, inhibition of
abnormal gene expression, inhibition of abnormal signal transduction, by encouraging
normal cell to cell communication, tumor angiogenesis inhibition, inhibition of
metastasis and increasing the immune response. Some anticancer drugs act by
inhibiting cancer cells growth and thereby causing cell death or by arresting cancer cell
proliferation because of molecular target interactions. In contrast, other drugs act by
inhibiting cell multiplication indirectly by inducing some changes in the local
environment, make it unfavorable for angiogenesis, invasion or metastasis.
Breast cancer is a significant health problem for women in the United States and
through out the world. Although advances have made in the treatment of the disease,
still breast cancer is the second leading cause of death for women in the United States.
No vaccine or any other successful method not available for breast cancer treatment.
Hormone therapy is very important treatment method for breast cancer since it is
commonly stimulated by estrogens and sex hormones. So, this cancer is treated with
anti cancer drugs that inactivate estrogens or limit the amount of estrogens in the body.
The drug blocks steroid hormone action and stops cancer cell replication by altering
hormone supplies. Tamoxifen is an estrogen antagonist, structurally related to the
synthetic estrogen diethylstilbestrol. Tamoxifen acts by inhibiting estrogen action that
is required to reduce the level of bioavailable estradiol that is necessary for breast
cancer cell growth.
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1.3 Some pharmaceutically important ethers:
Polybrominated di phenyl ether reported by Dian Handayani et al54, which is
antibacterial being active against Bacillus subtilis and anti fungal, being active against
fungi Cladosporium cucumerinum. Retinyl-2-propynyl ether activity of suppressing
mammary cancer reported by Fulmer shealy et al55. Morphine is a known analgesic.
Table 4 Structures of some bioactive ethers:
Structure of the compound
Br

Name of the compound

Br
O

Br

3, 4, 5-Tribromo-2-(2′bromophenoxy) phenol
HO

Br

Retinyl-2-propynyl ether
O

HO

HO

Morphine

N

O

H
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1.4 Podocarpic acid (13)
Podocarpic acid (13) is a natural conifer resin acid, which was isolated by Oudemans in
1873 from Podocarpus Cupressinum. It was extracted from ‘kahikatea’ tree
Podocarpus Dacrydioides and from ‘rimu’ tree Dacrydium Cupressinum.

Figure 13 Structure of Podocarpic acid (13)

Figure 14 Podocarpus Cupressinum
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Figure 15 Podocarpus Dacrydioides

Figure 16 Dacrydium Cupressinum
These are fast growing trees endemic in Newzealand, which is geographically shown in
figure 16
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Figure 17 Distribution of Podocarpus (blue areas) in world map
Podocarpic acid (13) has extracted by methanol from heart wood of podocarpus
species. Podocarpic acid has been used in Pharmaceutical industry35 and in the
preparation of soaps, paints and adhesives36. Podocarpic acid (13) is a white solid
material with melting point 195C. It is a natural diterpenoid with tricyclic framework
structure of phenanthrene. It has carboxylic acid and phenol functional groups. Because
of steric hindrance and due to diaxial interaction with C-10 methyl group carboxylic
acid moiety is unreactive37, 38 as shown below.

Figure 18 Podocarpic acid (13) conformation
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1.5 Previous studies done on podocarpic acid and its derivatives bioactivity:
Podocarpic acid (13) and its derivative podocarpinol’s (14) oestrogenic activity was
found back in 1948 by Brandt and Ross39.

(14) Podocarpinol

Podocarpic acid (13) has been utilized in the synthesis of anti-inflammatory and
antiviral agents40, 41, 42. Families of novel compounds containing lactones (cyclic esters)
and lactams (cyclic amides) have been synthesized from podocarpic acid. Examples of
derivatives of podocarpic acid are nimbiol (15) and winterin (16).

(15) Nimbiol
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(16) Winterin

Hayashi et al43 synthesized the biologically active dilactone, hydroxynagilactone (17)
from podocarpic acid in 1982.

(17) Hydroxynagilactone

Parish and Miles44 reported the antitumor activity of podocarpic acid derivatives such
as methyl-6α-bromo-7-oxo-O-methyl podocarpate (18) in 1984. They investigated
compound 18 activity against human epidermoid carcinoma of nasopharynx invitro.

39

(18) methyl-6α-bromo-7-oxo-O-methyl
podocarpate

In 1987, Parish45 et al synthesized several podocarpic acid derivatives, which showed
fungistatic activity. The most potent activity was shown by 11, 13-dinitropodocarpic
acid (19).

(19) 11, 13-dinitropodocarpic acid

In 1997, Eli lily and company conducted a study on the bioactivity of podocarpic acid
derivatives for treatment of bacterial and viral infections. The most potent46 drugs
reported were isopropyl-O-methyl podocarpate (20) and methyl-O-6-en-7-oxo-methyl
podocarpate (21).
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(20) Isopropyl-O-methyl podocarpate

(21) Methyl-O-6-en-7-oxo-methyl
podocarpate

In 1998, methyl-O-methyl podocarpate (22) was reported as antiviral agent. This
compound 22 showed antiviral activity47 by inhibiting replication of cells during
protein synthesis of influenza A/ Kawasaki virus.
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(22) methyl-O-methyl podocarpate

Adams48 et al., in 2003, synthesized the podocarpic acid derivative 23 to use as an
antihyperlipidemic agent (to treat conditions like depressed levels of HDL).
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2. Results and Discussion
The goal of this research was to synthesize a family of novel ether derivatives of
podocarpic acid (13) at the C-13 position of the aromatic ring as shown in figure 19.

Figure 19 Synthesis of ether derivatives of podocarpic acid (13)
Ethers are of great interest in organic synthesis because of their wide variety of uses. It
is known that aromatic amides can be prepared from aryl halides49. About hundred
years ago in 1903 Ulmann50 discovered the coupling of aryl bromide to form biaryl
compound. In 1926, Goldberg studied the formation of ethers from aryl bromide by
using copper catalyst. The reaction temperature of about 200C gave low yields of the
products and separations were difficult.
Palladium has been known as a catalyst for formation of ethers at moderate
temperatures with good yield. However palladium catalyst and phosphine ligands are
expensive. As a result, the search for inexpensive copper catalyst51, 52 was conducted
for coupling of an aryl halide with an alcohol to make an ether.
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The advantages of copper catalyst are that it is cheap and can be used in versatile
conditions such as in the presence of moisture or oxygen. Hence a copper catalyst was
used in the synthesis of novel ether derivatives of podocarpic acid.
The first step in this process was methylation of podocarpic acid (13) as described by
Miles53 to form methyl-O-methyl podocarpate (22) as shown in figure 20.

(22)

(13)

Figure 20 Formation of methyl-O-methyl podocarpate (22)

Compound 22 was formed in 84% yield and melting point was 127C. Spectroscopic
data such as IR, NMR and MS was consistent with the data shown53.
Iodination of compound 22 was performed by reacting compound 22 with iodine to
form 13-iodomethyl-O-methyl podocarpate (23) in 94% yield with a melting point of
149C. The spectroscopic data was consistent with the data shown.
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(22)

(23)

Figure 21 Formation of 13-iodomethyl-O-methyl podocarpate (23)
Compound 23 was then reacted with a series of aliphatic alcohols (see Table 5) to form
novel ethers at C-13 of podocarpic acid.

Table 5 Alcohols used in the synthesis of novel ethers from compound 23
Alcohol

Formula

Methanol

CH3-OH

Ethanol

CH3-CH2-OH

Propanol

CH3-CH2-CH2-OH
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(P)

(23)

Figure 22: General reaction for formation of novel ethers of podocarpic acid
Table 6 Attempts in the synthesis of ethers with various R groups
R

-CH3

-C2H5

-C3H7

Ether (P)

24

25

26

The general reaction involved mixing 1 molar equivalent of compound 23 with 1.5
molar equivalents of the corresponding alcohol and sodium alkoxide, 0.1 molar
equivalent of copper catalyst and 2 molar equivalent of potassium carbonate in N, N- di
methyl formamide at 110C and refluxing for four hours while monitoring the progress
of reaction with TLC. When the reaction was completed, the reaction mixture was
allowed to cool and the precipitate was obtained by vacuum filtration. Normal phase
open column chromatography was carried out on silica gel 70-230 mesh to obtain the
pure compound. The structure of each product was elucidated by IR, 1H NMR,
NMR and MS spectroscopy techniques.
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13

C

The reaction with methanol formed a new compound 13-methoxy methyl-O-methyl
podocarpate (24) in 84% yield with a melting point 143C. The IR, 1H NMR, 13C NMR
and MS spectra of compound 24 are shown below.

(24)

(23)

Figure 23 IR spectrum of compound 24
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The IR spectrum of compound 24 gave a signal at 1730 cm-1 corresponding to carbonyl
group of ester. The signals at 1450 cm-1, 1490cm-1 and 1600cm-1 correspond to the
aromatic ring. Strong absorption at 1200cm-1 corresponds to the C-O bond of ether and
ester.

(23)

Figure 24 1H NMR spectrum of compound 24
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The 1H NMR spectrum of compound 24 showed an additional peak at δ 3.62 ppm(s)
corresponding to methoxy group at C-13 position of podocarpic acid, in comparison to
1

H NMR spectrum of compound 23.

(23)

Figure 25

13

C NMR spectrum of compound 24
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The

13

C NMR spectrum of compound 24 gave peak at δ 57.2 ppm corresponding to

two equivalent carbons of methoxy groups at C-13 and at C-12 of compound 24. The
chemical shift of aromatic carbons was more downfield compared to compound 23.

m/z
Figure 26 Mass spectrum of compound 24

The mass spectrum showed molecular ion m/z at 332.4 corresponding to molecular
formula of C20H28O4. The peak at m/z 302.1 represented methyl-O-methyl podocarpate
formed because of cleavage of C-O bond at C-13 position of compound 24. The base
peak was given at 154.1 corresponding to [M-178]+. Basic fragmentation pattern for
compound 24 is shown in figure 27.
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M-31
-OCH3

m/z 332

m/z 301
-2CH3, -COOCH3,
-147 -OCH , -C H
3
2 2

m/z 154

Figure 27 Fragmentation pattern of compound 24
Therefore from all the spectroscopic data obtained, compound 24 was found to be 13methoxy methyl-O-methyl podocarpate. The structure of compound 24 is shown in
figure 28.
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Figure 28 Structure of compound 24
Compound 25 was formed in 88% yield with a m.p of 146C. The IR, 1H NMR,

13

C

NMR, MS spectra of compound 25 are shown in figures 29, 30, 31 and 32 respectively.

Figure 29 IR spectrum of compound 25
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The IR spectrum of compound 25 gave a signal at 1730 cm-1 corresponding to carbonyl
group of ester. The signals at 1450 cm-1, 1490cm-1 and 1600cm-1 correspond to the
aromatic ring. The strong absorption at 1200cm-1 corresponds to C-O bond of ether and
ester.

(23)

Figure 30 1H NMR spectrum of compound 25
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The 1H NMR spectrum gave new signal at δ 3.98 ppm (q) which could be assigned to
the CH2-O moiety that is present in the compound 25. Methyl group attached to CH2-O
moiety gave signal at δ 1.33 ppm (t). Two methoxy groups from ether and ester gave
signals at δ 3.85 (s) and δ 3.95 ppm (s) respectively.

(23)

Figure 31

13

C NMR spectrum of compound 25
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The

13

C NMR of compound 25 showed new signals at δ 65 ppm and 14.8 ppm

corresponding to CH2-O and CH3 respectively. Signals appeared down field compared
to compound 23.

m/z
Figure 32 MS of compound 25

The mass spectrum of compound 25 showed a molecular ion at m/z 346.4, which was
consistent with molecular formula C21H30O4. The peak at m/z 302.4 corresponded to
methyl-O-methyl podocarpate and could be the result of cleavage of the C-O bond at C13 of compound 25. The basic fragmentation pattern for compound 25 is shown in
figure 33.
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OCH3
OCH2CH3

M-45

Me

COOMe

m/z 346
m/z 301
-2CH3, -COOCH3,
-147 -OCH , -C H
3
2 2

m/z 154

Figure 33 Basic fragmentation pattern for compound 25
Therefore compound 25 can be confirmed as 13-ethoxy methyl-O-methyl
podocarpate. The structure of compound 25 is shown in figure 34.
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OCH3
OCH2CH3

Me

COOMe

m/z 346

Figure 34 Structure of compound 25

Compound 26 was formed in 84% yield with a m.p of 148C. The IR, 1H NMR,
NMR and MS spectra

13

C

were obtained and shown in figures 35, 36, 37 and 38

respectively.

Figure 35 IR spectrum of compound 26
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The IR spectrum of compound 26 gave a signal at 1220 cm-1, corresponding to the C-O
group of ether and ester that were present in compound 26. Absorptions for the
aromatic ring were present at 1400 cm-1, 1490cm-1 and 1600 cm-1.

(23)

Figure 36 1H NMR spectrum of compound 26
The 1H NMR spectrum of compound 26 showed two singlets at δ 6.62 ppm and δ 6.78
ppm for aromatic protons on benzene ring. The protons of methoxy groups appeared at
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δ 3.65 and δ 3.78 ppm. The protons of propyl group appeared at, δ 3.95 ppm (t) for the
methylene group attached to oxygen, δ 1.75 ppm (sextet) for methylene group and δ
1.10 ppm (t) for methyl group.

(23)

Figure 37 13C NMR spectrum of compound 26
13

C NMR of compound 26 showed twenty two signals for twenty two different carbons

present in the compound 26. Seven carbons with the chemical shift down field from δ
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100 ppm. The methylene attached to oxygen gave a signal at δ 73.5 ppm while a methyl
group came at δ 14.2 ppm. Methylene group absorption was present at δ 22.7 ppm. A
total fifteen carbons were present with the chemical shift up field from δ 100 ppm.

m/z
Figure 38 MS of compound 26
The MS of compound 26 displayed a molecular ion peak at m/z 360.2, which is
consistent with the molecular formula C22H32O4. The m/z 302.1 resulted from the
cleavage of C-O bond at C-13 of compound 26. Further fragmentation gave the base
peak at m/z 154.1 as shown in figure 40.
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OCH3
OCH2CH2CH3

M-59
-OCH2CH2CH3
Me

COOMe

m/z 360
m/z 301
-2CH3, -COOCH3,
-147 -OCH , -C H
3
2 2

m/z 154

Figure 39 Basic fragmentation pattern of compound 26
Therefore the compound 26 can be confirmed as 13-propoxy methyl-O-methyl
podocarpate. Structure of compound 26 is shown in figure 40.
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Figure 40 Structure of compound 26
In the summary the reaction of 13-iodo methyl-O-methyl podocarpate (23) with
aliphatic alcohols gave ether derivatives of podocarpic acid in high yield (between 84
and 88 %). Three new ether derivatives of podocarpic acid were synthesized and their
activity against cancer will be tested by National Cancer Institute against 60 cancer cell
lines and activity against tuberculosis will be performed by National Institute for
Allergies, Infections and Diseases. Thus this work may result in a new drug lead useful
for the treatment of human ailments/diseases.
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3. Experimental

3.1 Preparation of methyl-O-methyl podocarpate (22)
25 g of crude podocarpic acid was weighed in a 300 mL beaker and 25 g of ice was
added into it. Then 25 mL of methanol was added to the beaker. This mixture was
stirred then added 12 g pellets of sodium hydroxide. The solution was continually
stirred to dissolve completely the podocarpic acid and sodium hydroxide, then it was
0

cooled to 15 C in an ice bath. 21.5 mL of dimethyl sulfate was added into this solution
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in a period of 1 hour . At the end this period, this solution solidified. This mixture was
stirred for an addition of 30 minutes then added 50 mL water then it was filtered. The
solid was dissolved in 50 mL water then filtered and dried to obtain 22 g a white solid.
This solid was recrystallized to obtain 20 g of methyl-O-methylpodocarpate with m.p.
of 125C. Yield was 82%. IR (Perkin Elmer Spectrometer, CHCl ):3000, 2950, 2900,
3

2860, 1720, 1600, 1540, 1490, 1460, 1400, 1360, 1300, 1240, 1200, 1190, 1150, 1060,
-1 1

1020950, 760, 740 cm . H-NMR (Mercury 300 MHz): 6.95 (d), 6.8 (s), 6.65 (d), 3.85
(s), 3.65 (s), 2.8 (m), 2.25 (m), 1.95 (m), 1.6 (m), 1.5 (m), 1.4 (m), 1.22 (m), 1.2 (s),
13

1.15 (m), 1.05 (m), 1.00 (s) ppm. C-NMR (Mercury 300 MHz): 178, 158, 150, 130,
128, 114, 112, 56, 52, 51, 44, 39.5, 38, 31, 28, 25, 22.5, 20.5, 20 ppm. MS: 302(44),
287(6), 228(16), 227(100), 173(6), 170(23), 147(10), 121(6), 91(4).
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3.2 Preparation of 13-Iodomethyl-O-Methylpodocarpate (23)
3.025 g of methyl-O-methylpodocarpate was weighed and transferred into a 500 mL
volumetric flask, and then it dissolved in 60 mL of acetic acid. In a separated beaker, 2
g of mercury (II) acetate was weighed and dissolved in 60 mL of acetic acid, and then
this content was added into the flask above. This solution was heated to 70C and stirred
for 15 minutes. A solution of iodine was prepared by dissolving of 7.614 g of iodine in
240 mL of warm acetic acid. This iodine solution was then added drop wise in a period
of 45 minutes into the flask while the temperature maintained at 70C during this period.
At the end of this period, the solution was stirred for an addition 1 hour then cooled the
flask to 15C in an ice bath, the solution was filtrated and the filtrate was added into 500
mL of cold water in a 1L beaker. The resulting precipitate was filtered to yield 3 g of
product. The product was recrystallized from acetone to obtain 2 g of pure product with
m.p.149C, yield95%. IR (Perkin Elmer Spectrometer, CHCl ): 3000, 2940, 2850, 2400,
3

1720, 1600, 1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050, 950, 900,
800, 750, 650 cm-1.1H-NMR (Mercury 300 MHz):7.45(s), 6.65 (s), 3.95 (s), 3.85 (s),
2.70 (m), 2.20 (m), 1.95(m), 1.6 (m), 1.5 (m), 1.25 (s), 1.15 (m), 1.02 (s), 0.95 (m) ppm.
13

C-NMR (Mercury 300 MHz): 178, 156, 150, 140, 131, 108, 83, 56.5, 52.5, 52, 44, 39,

38.5, 32, 31.5, 29.5, 23, 21, 20 ppm. HRMS (Finnegan Spectrometer): 428(100),
413(8), 381(3), 368(3), 353(77), 313(4), 287(6), 272(6), 227(15), 211(4), 172(6),
140(5),129(8),115(6),101(3),91(2).
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3.3 Preparation of 13-methoxy methyl-O-methyl podocarpate (24)
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom
flask and dissolved in 0.32 g of N, N-dimethyl formamide. 0.405 g of sodium
methoxide was added to 0.34g of methanol in a separate beaker. The content inside the
beaker was added to the flask and magnetic stirrer was added. Then the flask was
heated by using heating mantle with continuous stirring till the temperature of solution
reached 110C. At 110C, 0.1 g Copper (I) iodide was added. Then condenser was
connected and reflux at 110C for four hours while monitoring the reaction with TLC.
After the completion of the reaction, the solution was allowed to cool. The precipitate
formed and filtered. The precipitate was washed with 100 mL ethyl acetate. The filtrate
was evaporated to obtain 2 g of solid. Normal phase open column chromatography was
performed to obtain 0.58 g 13-methoxy methyl-O-methyl podocarpate with m.p 143C.
Yield was 84%. IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400,
1720, 1600, 1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H
NMR (Mercury 300 MHz): 7.52(s), 7.32(s), 6.73(s), 3.95(s), 3.85(s), 3.62(s), 2.80(m),
2.28(m), 2.02(m), 1.64(m), 1.30(s), 1.22(s), 0.81(s) ppm.

13

C NMR (Mercury 300

MHz): 178, 158, 151, 148, 146.1, 132, 110.5, 57.2, 52, 50.2, 44.3, 38, 36, 30, 28, 22,
20, 18 ppm. MS (Finnegan spectrometer): 333.4(30), 332(14), 302.4(82), 220.3(18),
155.1(100).
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3.4 Preparation of 13-ethoxy methyl-O-methyl podocarpate (25)
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom
flask and dissolved in 5 mL of N, N-dimethyl formamide. 0.51 g of sodium ethoxide
was added to 0.54g of ethanol in a separate beaker. The content inside the beaker was
added to the flask and magnetic stirrer was added. Then the flask was heated by using
heating mantle with continuous stirring till the temperature of solution reached 110C.
At 110C, 0.1 g Copper (I) iodide was added. Then condenser was connected and reflux
at 110C for four hours while monitoring the reaction with TLC. After the completion
of the reaction, the solution was allowed to cool. The precipitate formed and filtered.
The precipitate was washed with 100 mL ethyl acetate. The filtrate was evaporated to
obtain 2 g of solid. Normal phase open column chromatography was performed to
obtain 0.64 g 13-ethoxy methyl-O-methyl podocarpate with m.p 146C. Yield was 88%.
IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400, 1720, 1600, 1495,
1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H NMR (Mercury 300
MHz): 7.45(s), 7.25(s), 4.04(m), 3.95(s), 3.85(s), 2.80(m), 2.28(m), 2.02(m), 1.64(m),
1.30(s), 1.22(s), 0.81(s) ppm.

13

C NMR (Mercury 300 MHz): 178, 150, 142, 140,132,

108, 106, 65.2, 56, 52.2, 44.3, 40, 36, 30, 28, 22, 20, 18, 14 ppm. MS (Finnegan
spectrometer): 347.4(25), 346 (10), 302.4(58), 220.3(18), 155.1(100).
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3.5 Preparation of 13-propoxy methyl-O-methyl podocarpate (26)
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom
flask and dissolved in 5 mL of N, N-dimethyl formamide. 0.55 g of sodium propoxide
was added to 0.54g of propanol in a separate beaker. The content inside the beaker was
added to the flask and magnetic stirrer was added. Then the flask was heated by using
heating mantle with continuous stirring till the temperature of solution reached 110C.
At 110C, 0.1 g Copper (I) iodide was added. Then condenser was connected and reflux
at 110C for four hours while monitoring the reaction with TLC. After the completion
of the reaction, the solution was allowed to cool. The precipitate formed and filtered.
The precipitate was washed with 100 mL ethyl acetate. The filtrate was evaporated to
obtain 2.2 g of solid. Normal phase open column chromatography was performed to
obtain 0.67 g 13-propoxy methyl-O-methyl podocarpate with m.p 148C. Yield was
84%. IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400, 1720, 1600,
1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H NMR (Mercury
300 MHz): 6.82(s), 6.73(s), 4.01(m), 3.95(s), 3.85(s), 3.12(m), 1.80(m), 1.60(m),
1.40(s), 1.02(s), 0.81(s) ppm. 13C NMR (Mercury 300 MHz): 178, 146, 144, 142, 132,
110.5, 108.2, 70.4, 58, 53.8, 52, 44.3, 38, 36, 32, 30, 28, 22, 20, 19, 18, 14 ppm. MS
(Finnegan spectrometer): 361.2(16), 360(5), 302(68), 220.3(18), 155.1(100).
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